

DAFTAR PUSTAKA

- Abu-Khalaf, M.M., Hodge, K.A., Hatzis, C., Baldelli, E., El Gazzah, E., Valdes, F., Sikov, W.M. et al. (2023) 'AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers', *NPJ Precision Oncology*, 7. Available at: <https://doi.org/10.1038/s41698-023-00360-5>.
- Amin, M.B., Edge, S.B., Greene, F.L., Byrd, D.R., Brookland, R.K., Washington, M.K., Gress, D.M., Meyer, L.R. and Winchester, D.P. (eds.) (2017) *AJCC Cancer Staging Manual*. 8th edn. New York: Springer International Publishing.
- Alves, C.L. and Ditzel, H.J. (2023) 'Drugging the PI3K/AKT/mTOR pathway in ER+ breast cancer', *International Journal of Molecular Sciences*. Available at: <https://doi.org/10.3390/ijms24054522>.
- Ardhiansyah, A.O. (2021) *Kanker Payudara: dari Teori Preklinik Hingga Aplikasi Klinik*. 2nd edn. Surabaya: Airlangga University Press.
- Bachelot, T., Bourcier, C., Cropet, C., Ray-Coquard, I., Ferrero, J.M., Freyer, G. et al. (2012) 'Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study', *Journal of Clinical Oncology*, 30(22), pp. 2718–2724. doi: 10.1200/JCO.2011.39.0708.
- Baselga, J., Campone, M., Piccart, M., Burris, H.A., Rugo, H.S., Sahmoud, T. et al. (2012) 'Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer', *New England Journal of Medicine*, 366(6), pp. 520–529. doi: 10.1056/NEJMoa1109653.
- Belachew, E.B. and Sewasew, D.T. (2021) 'Molecular mechanisms of endocrine resistance in estrogen-positive breast cancer', *Frontiers in Endocrinology (Lausanne)*. Available at: <https://doi.org/10.3389/fendo.2021.599586>.
- Bose, R. and Bhatt, D.L. (2022) 'PIK3CA mutations in breast cancer: biology, clinical significance, and therapeutic implications', *Journal of Clinical Oncology*, 40(14), pp. 1553–1557.
- Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I. and Jemal, A. (2024) 'Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries', *CA: A Cancer Journal for Clinicians*, 74, pp. 229–263. Available at: <https://doi.org/10.3322/caac.21834>.
- Calvanese, L., Maximo, V., Pinheiro, J., Leal, P., Soares, P. and Sobrinho-Simoes, M. (2023) 'mTOR inhibition is superior to PI3K inhibition in overcoming tamoxifen and CDK4/6 inhibitor resistance in luminal breast cancer models irrespective of PIK3CA mutation status', *Cancers*, 15(3), p. 686. doi: 10.3390/cancers15030686.
- Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., André, F. et al. (2020) '6th ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 6)', *Annals of Oncology*, 31(12), pp. 1623–1649. doi: 10.1016/j.annonc.2020.09.010.
- Cerma, K., Piacentini, F., Moscetti, L., Barbolini, M., Canino, F., Tornincasa, A. et al. (2023) 'Targeting PI3K/AKT/mTOR pathway in breast cancer: from biology to clinical challenges', *Biomedicines*. Available at: <https://doi.org/10.3390/biomedicines11010109>.
- Cheang, M.C.U., Chia, S.K., Voduc, D., Gao, D., Leung, S., Snider, J. et al. (2009) 'Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer', *Journal of the National Cancer Institute*, 101(10), pp. 736–750. doi: 10.1093/jnci/djp082.
- Cheng, T.Y.D., Omilian, A.R., Yao, S., Sanchez, P.V., Polk, L.K., Zhang, W. et al., (2020, "Body fatness and mTOR pathway activation of breast cancer in the Women's Circle of Health Study, npj Breast cancer, vol.6, article 45, pp. 1-9,. Doi:10.1038/s41523-020-00187-4.
- DeVita, V.T., Lawrence, T.S. and Rosenberg, S.A. (2019) *DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology*. 11th edn. Philadelphia: Wolters Kluwer.

- Dowsett, M., Allred, D.C. and Knox, J. (2005) 'Relationship between quantitative estrogen and progesterone receptor expression and human breast cancer recurrence', *Journal of Clinical Oncology*, 23(21), pp. 5148–5157.
- EORTC Breast Cancer Cooperative Group (2000) 'Menopause criteria in breast cancer clinical trials', *European Journal of Cancer*, 36(Suppl 2), p. S2.
- Elston, C.W. and Ellis, I.O. (2020) 'Pathological prognostic factors in breast cancer: the value of histological grade in breast cancer', *Histopathology*, 41(3A), pp. 154–161. doi: 10.1046/j.1365-2559.2002.14980.x.
- Francis, P.A., Pagani, O., Fleming, G.F., Walley, B.A., Colleoni, M., Láng, I. et al. (2018) 'Tailoring adjuvant endocrine therapy for premenopausal breast cancer', *New England Journal of Medicine*, 379(2), pp. 122–137. doi: 10.1056/NEJMoa1803164.
- Garudanto, G.G., Wahyono, R.A. and Rinonce, H.T. (2017) Hubungan Antara Ekspresi mTOR Dengan Ukuran Tumor dan Stadium Pada Penderita Karsinoma Payudara Operabel. Undergraduate thesis. Universitas Gadjah Mada. Available at: <https://etd.repository.ugm.ac.id/penelitian/detail/111921>.
- Gennari, A., André, F., Barrios, C.H., Cortés, J., de Azambuja, E., DeMichele, A. et al. (2021) 'ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer', *Annals of Oncology*, 32(12), pp. 1475–1495. Available at: <https://doi.org/10.1016/j.annonc.2021.09.019>.
- Giaquinto, A.N., Sung, H., Miller, K.D., Kramer, J.L., Newman, L.A., Minihan, A., Jemal, A. and Siegel, R.L. (2022) 'Breast cancer statistics, 2022', *CA: A Cancer Journal for Clinicians*, 72(6), pp. 524–541. doi: 10.3322/caac.21754.
- GLOBOCAN (2022) Global Cancer Observatory: Cancer Today. Lyon: International Agency for Research on Cancer. Available at: <https://gco.iarc.fr/today>.
- Goldhirsch, A., Wood, W.C., Coates, A.S., Gelber, R.D., Thürlimann, B. and Senn, H.J. (2011) 'Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011', *Annals of Oncology*, 22(8), pp. 1736–1747. doi: 10.1093/annonc/mdr304.
- Goldhirsch, A., Winer, E.P., Coates, A.S., Gelber, R.D., Piccart-Gebhart, M., Thürlimann, B. and Senn, H.J. (2013) 'Personalizing the treatment of women with early breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013', *Annals of Oncology*, 24(9), pp. 2206–2223. doi: 10.1093/annonc/mdt303.
- Hanahan, D. (2022) 'Hallmarks of cancer: new dimensions', *Cancer Discovery*. Available at: <https://doi.org/10.1158/2159-8290.CD-21-1059>.
- Hanahan, D. and Weinberg, R.A. (2011) 'Hallmarks of cancer: the next generation', *Cell*, 144(5), pp. 646–674. doi: 10.1016/j.cell.2011.02.013.
- Hussain, M., Bhatt, S., Bhatt, D., Mukherjee, A. and Gupta, P. (2022) 'Hypoxia, PI3K/AKT/mTOR signalling and drug resistance in breast cancer', *Molecular Biology Reports*, 49, pp. 3979–3988.
- Johnston, S., Martin, M., Di Leo, A., Cameron, D., Jonsson, P., Jassem, J. et al. (2014) 'MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer', *NPJ Breast Cancer*, 5, p. 5. doi: 10.1038/s41523-018-0097-z.
- Kementerian Kesehatan Republik Indonesia (2019) Infodatin: Beban Kanker di Indonesia. Jakarta: Kementerian Kesehatan Republik Indonesia.
- Kementerian Kesehatan Republik Indonesia (2022) Laporan Nasional Risesdas 2022: Data Kanker di Indonesia. Jakarta: Badan Penelitian dan Pengembangan Kesehatan.
- Leary, A.F., Saini, K.S. and Turner, N. (2016) 'Molecular pathways and biomarkers of endocrine resistance', *Breast*, 26, pp. 57–65.
- Lemeshow, S., Hosmer, D.W., Klar, J. and Lwanga, S.K. (1997) Besar Sampel dalam Penelitian Kesehatan. Yogyakarta: Gadjah Mada University Press.

- Loibl, S., André, F., Bachelot, T., Barrios, C.H., Bergh, J., Burstein, H.J. et al. (2024) 'Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up', *Annals of Oncology*, 35(2), pp. 159–182. Available at: <https://doi.org/10.1016/j.annonc.2023.11.016>.
- Manopo, A., Tjindarbumi, D., Pieter, J., Darwis, I., Ramli, M., Lukito, P. et al. (2020) 'Panduan Penatalaksanaan Kanker Payudara', in Handojo, D., Haryono, S.J., Sudarsa, I.W., Panigoro, S.S., Setiaji, K., Tanggo, E.H. and Wismra, A.H. (eds.) *Panduan Penatalaksanaan Kanker 2020*. Jakarta: PERABOI, pp. 1–40.
- Marques-Ramos, A. and Cervantes, R. (2023) 'Expression of mTOR in normal and pathological conditions', *Molecular Cancer*, 22(1), p. 112. doi: 10.1186/s12943-023-01820-z.
- Massarweh, S. and Schiff, R. (2006) 'Mechanisms of endocrine resistance in breast cancer', *Nature Clinical Practice Oncology*, 3(12), pp. 650–660.
- Miller, T.W. (2013) 'Endocrine resistance: what do we know?', *American Society of Clinical Oncology Educational Book*. doi: 10.14694/EdBook_AM.2013.33.e37.
- Miller, T.W., Hennessey, B.T., Gonzalez-Angulo, A.M., Fox, E.M., Mills, G.B., Chen, H. et al. (2011) 'Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer', *Journal of Clinical Investigation*, 121(7), pp. 2688–2700. doi: 10.1172/JCI45168.
- Miricescu, D., Totan, A., Stanescu-Spinu, I.I., Badoiu, S.C., Stefani, C. and Greabu, M. (2020) 'PI3K/AKT/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects', *International Journal of Molecular Sciences*, 22(1), p. 173. doi: 10.3390/ijms22010173.
- Miziak, P., Baran, M., Błaszczak, E., Przybyszewska-Podstawka, A., Kałafut, J., Smok-Kalwat, J. et al. (2023) 'Estrogen receptor signaling in breast cancer', *Cancers (Basel)*. Available at: <https://doi.org/10.3390/cancers15194689>.
- Mukhopadhyay, P., Lebwohl, D. and Hortobagyi, G.N. (2012) 'Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer', *New England Journal of Medicine*, 366(6), pp. 520–529. doi: 10.1056/NEJMoa1109653.
- Muyasarah, K., Wahyono, R.A., Rinonce, H.T. and Irianiwati (2019) *Hubungan Antara Ekspresi mTOR Dengan Stadium Prognostik Karsinoma Payudara Operabel*. Undergraduate thesis. Universitas Gadjah Mada. Available at: <https://etd.repository.ugm.ac.id/penelitian/detail/174871>.
- National Comprehensive Cancer Network (2025) *NCCN Clinical Practice Guidelines in Oncology: Breast Cancer*. Version 1.2025. Plymouth Meeting, PA: NCCN. Available at: <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419>.
- Noe, J.F. and Bush, V.N. (2021) 'Endocrine therapy for breast cancer', *The Journal for Nurse Practitioners*, 17(2), pp. 177–181. Available at: <https://doi.org/10.1016/j.nurpra.2020.10.015>.
- Osborne, C.K. and Schiff, R. (2011) 'Mechanisms of endocrine resistance in breast cancer', *Annual Review of Medicine*, 62, pp. 233–247. doi: 10.1146/annurev-med-070909-182917.
- Panjari, M., Bell, R., Lijovic, M., La China, M., Schwarz, M., Fradkin, P. et al. (2010) 'The relationship between hormone therapy use at the time of diagnosis of breast cancer and tumor characteristics', *Hormones and Cancer*, 1(2), pp. 93–99. doi: 10.1007/s12672-010-0011-0.
- Paplomata, E. and O'Regan, R. (2014) 'The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers', *Therapeutic Advances in Medical Oncology*, 6(4), pp. 154–166. doi: 10.1177/1758834014530023.
- Parker, J.S., Mullins, M., Cheang, M.C.U. et al. (2009) 'Supervised risk predictor of breast cancer based on intrinsic subtypes', *Journal of Clinical Oncology*, 27(8), pp. 1160–1167.
- Perou, C.M., Sørlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S. and Rees, C.A. et al. (2000) 'Molecular portraits of human breast tumours', *Nature*, 406, pp. 747–752. Available at: <https://doi.org/10.1038/35021093>.
- Presti, D. and Quaquarini, E. (2019) 'The PI3K/AKT/mTOR and CDK4/6 pathways in endocrine resistant

- HR+/HER2- metastatic breast cancer: biological mechanisms and new treatments', *Cancers* (Basel), 11(9). Available at: <https://doi.org/10.3390/cancers11091242>.
- Qian, J., Su, S. and Liu, P. (2020) 'Experimental approaches in delineating mTOR signaling', *Genes*, 11(7), p. 738. Available at: <https://doi.org/10.3390/genes11070738>.
- Rakha, E.A., Reis-Filho, J.S. and Ellis, I.O. (2010) 'Basal-like breast cancer: a critical review', *Journal of Clinical Oncology*, 28(3), pp. 504–508.
- Robertson, J.F.R., Sainsbury, R. and Wardley, A. (1999) 'Tamoxifen as adjuvant therapy: clinical outcomes', *European Journal of Cancer*, 35(1), pp. 39–46.
- Robinson, D.R., Wu, Y.M., Vats, P., Su, F., Lonigro, R.J., Cao, X. et al. (2013) 'Activating ESR1 mutations in hormone-resistant metastatic breast cancer', *Nature Genetics*, 45(12), pp. 1446–1451. doi: 10.1038/ng.2823.
- Rodriguez, M.J., Perrone, M.C., Riggio, M., Palafox, M., Salinas, V. and Elia, A. (2023) 'Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models', *Scientific Reports*, 13, p. 2710. Available at: <https://doi.org/10.1038/s41598-023-29425-y>.
- Roshan, K.M., Soltani, A., Soleimani, A., Rezaie, K.K., Afshari, A.R. and Soukhtanloo, M. (2019) 'Role of AKT and mTOR signaling pathways in the induction of epithelial-mesenchymal transition (EMT) process', *Biochimie*. doi: 10.1016/j.biochi.2019.08.003.
- Rotundo, M.S., Galeano, T., Tassone, P. and Tagliaferri, P. (2016) 'mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials', *Cancer Treatment Reviews*, 51, pp. 76–84.
- Rugo, H.S., Vidula, N. and Ma, C. (2016) 'Improving response to hormone therapy in breast cancer: new targets, new therapeutic options', *American Society of Clinical Oncology Educational Book*, 36. Available at: https://doi.org/10.1200/EDBK_159198.
- Saxton, R.A. and Sabatini, D.M. (2017) 'mTOR signaling in growth, metabolism and disease', *Cell*, 168(6), pp. 960–976.
- Shete, N., Calabrese, J. and Tonetti, D.A. (2023) 'Revisiting estrogen for the treatment of endocrine-resistant breast cancer: novel therapeutic approaches', *Cancers*, 15(14), p. 3647. Available at: <https://doi.org/10.3390/cancers15143647>.
- Sørli, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S. and Johnsen, H. et al. (2001) 'Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications', *Proceedings of the National Academy of Sciences*, 98, pp. 10869–10874. Available at: <https://doi.org/10.1073/pnas.191367098>.
- Wahyono, R.A. (2018) Hubungan antara ekspresi autophagy related protein Beclin 1 dan mTOR dengan karakteristik klinikopatologik, rekurensi, dan ketahanan hidup pada penderita kanker payudara operabel. PhD dissertation. Universitas Gadjah Mada, Yogyakarta. Available at: <https://etd.repository.ugm.ac.id/penelitian/detail/159923>.
- Wander, S.A., Zhao, D., Besser, A.H., Hong, F., Wei, J., Ince, T.A. et al. (2013) 'PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy', *Breast Cancer Research and Treatment*, 138, pp. 369–381. Available at: <https://doi.org/10.1007/s10549-012-2389-6>.
- Zhu, K., Wu, Y., He, P., Fan, Y., Zhong, X., Zheng, H. and Luo, T. (2022) 'PI3K/AKT/mTOR-targeted therapy for breast cancer', *Cells*. Available at: <https://doi.org/10.3390/cells11162508>.
- Zou, Z., Tao, T., Li, H. and Zhu, X. (2020) 'mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges', *Cell and Bioscience*, 10, p. 31. Available at: <https://doi.org/10.1186/s13578-020-00396-1>.
- World Health Organization (2022) WHO Classification of Tumours: Breast Tumours. 5th edn. Lyon: International Agency for Research on Cancer (IARC Press). ISBN: 978-92-832-4500-9.